Array Technologies (ARRY) Soars 44% Over Last Month

Array Technologies (ARRY) announced the verification of its DuraTrack® and OmniTrack™ systems for 2,000-volt compatibility, reflecting its focus on enhancing solar efficiency and reducing costs. This announcement may have contributed to the company's impressive 44% price increase over the last month, supporting its leadership position in the solar sector. This price move occurred as the broader market indices hit all-time highs, with the S&P 500 and Nasdaq rising and inflation metrics ticking lower. While the general market trend was upward, Array's advancements in technology and alignment with industry standards likely added weight to its stock performance.

You should learn about the 1 weakness we've spotted with Array Technologies.

ARRY Earnings Per Share Growth as at Sep 2025
ARRY Earnings Per Share Growth as at Sep 2025

Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

The recent verification of Array Technologies' DuraTrack and OmniTrack systems for 2,000-volt compatibility is a significant milestone that aligns well with the company's narrative of driving utility-scale solar growth through innovative products. This technological enhancement may bolster Array's competitive positioning and contribute positively to revenue and earnings forecasts. With analysts projecting an 8.6% annual revenue growth over three years, such innovations could further stabilize margins and enhance profitability projections, supporting the company's ongoing expansion and market share growth.

Over the past year, Array Technologies' total shareholder return was a substantial 39.19% driven by price movements rather than dividends. This performance trajectory contrasts with the previous 46.8% per year increase in losses over the past five years. Despite a challenging landscape, Array outperformed the overall US market, which returned 20.5%. However, it underperformed the US Electrical industry, which saw a 52% return.

Given the current share price of $7.92 and a consensus price target of approximately $9.30, the recent share price increase indicates confidence in the upcoming performance, although the difference from the price target remains modest. Investors are urged to consider these factors in their evaluations, especially in light of Array's ambitious international expansion and evolving product offerings, which could potentially reduce the share price discount to analyst targets.

Insights from our recent valuation report point to the potential undervaluation of Array Technologies shares in the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:ARRY

Array Technologies

Engages in the manufacture and sale of solar tracking technology products in the United States, Spain, Brazil, Australia, and internationally.

Undervalued with excellent balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
204 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

ON
LOT logo
Ontological on Lotus Technology ·

Lotus Tech, Finloop and FOMO Pay Collaborate to Explore Vehicle Tokenization

Fair Value:US$2.463.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
NE
AIIO logo
newsfinder11221 on Robo.ai ·

Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution

Fair Value:US$540.4% undervalued
1 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
87 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
196 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
73 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0